Brightlands Venture Partners

Matthijs Bremer thanks for the interview at Foodbusiness about investing in innovations that add to a sustainable agri-food system in N-W Europe. And make this region a frontrunner in the transformation towards a sustainable agri-food system globally.

🚨 Another exciting update from Matisse Pharmaceuticals B.V. - a BVP portfolio company developing the first life-saving treatment targeting the root cause of sepsis 𝗠𝗮𝘁𝗶𝘀𝘀𝗲 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 𝗿𝗲𝗰𝗲𝗶𝘃𝗲𝘀 𝗕𝗳𝗔𝗿𝗠 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝘁𝗼 𝘀𝘁𝘂𝗱𝘆 𝗮 𝗽𝗿𝗼𝗹𝗼𝗻𝗴𝗲𝗱 𝗶𝗻𝗳𝘂𝘀𝗶𝗼𝗻 𝗼𝗳 𝗠𝟲𝟮𝟮𝟵 🥼 Matisse Pharmaceuticals B.V., a clinical stage company developing a medicinal product for the treatment of sepsis, today announced that it received green light from the BfArM (German Regulatory Authorities) to start a phase 1 study evaluating the safety, tolerability & pharmacokinetics of a prolonged intravenous (IV) infusion with its lead compound M6229. “𝘙𝘦𝘤𝘦𝘪𝘷𝘪𝘯𝘨 𝘉𝘧𝘈𝘳𝘔 𝘢𝘱𝘱𝘳𝘰𝘷𝘢𝘭 𝘵𝘰 𝘤𝘰𝘯𝘥𝘶𝘤𝘵 𝘵𝘩𝘪𝘴 𝘱𝘩𝘢𝘴𝘦 1 𝘵𝘳𝘪𝘢𝘭 𝘪𝘴 𝘢 𝘮𝘢𝘫𝘰𝘳 𝘮𝘪𝘭𝘦𝘴𝘵𝘰𝘯𝘦 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘤𝘰𝘮𝘱𝘢𝘯𝘺. 𝘞𝘪𝘵𝘩 𝘵𝘩𝘪𝘴 𝘢𝘱𝘱𝘳𝘰𝘷𝘢𝘭, 𝘔𝘢𝘵𝘪𝘴𝘴𝘦 𝘵𝘢𝘬𝘦𝘴 𝘢𝘯𝘰𝘵𝘩𝘦𝘳 𝘴𝘵𝘦𝘱 𝘪𝘯 𝘣𝘳𝘪𝘯𝘨𝘪𝘯𝘨 𝘢 𝘩𝘪𝘨𝘩𝘭𝘺 𝘯𝘦𝘦𝘥𝘦𝘥 𝘦𝘧𝘧𝘦𝘤𝘵𝘪𝘷𝘦 𝘴𝘦𝘱𝘴𝘪𝘴 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘤𝘭𝘰𝘴𝘦𝘳 𝘵𝘰 𝘵𝘩𝘦 49 𝘮𝘪𝘭𝘭𝘪𝘰𝘯 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘴𝘶𝘧𝘧𝘦𝘳𝘪𝘯𝘨 𝘧𝘳𝘰𝘮 𝘴𝘦𝘱𝘴𝘪𝘴 𝘦𝘷𝘦𝘳𝘺 𝘺𝘦𝘢𝘳” - Marcel Jacobs, CEO 𝗣𝗵𝗮𝘀𝗲 𝟭 𝗱𝗲𝘀𝗶𝗴𝗻 🔬 The study will consist of single-blind, randomized, placebo-controlled, IV infusion cohorts, in which the safety, tolerability and PK of M6229 will be assessed in healthy volunteers when administered continuously for 120 hours. Matisse expects to enroll the first healthy volunteer in November 2024. The study will be executed and managed by Charité Research Organisation located in Berlin, Germany. ⚕️ In Matisse’s first and successful human clinical trial in severely ill sepsis patients, finalized earlier this year, a 6 hour continuous IV infusion was applied. The study showed favorable safety and tolerability as well as close to dose-proportional pharmacokinetics of IV administered M6229 in critically ill patients with sepsis. The study also showed pharmacodynamic effects on histones, CRP levels and SOFA scores. “𝘞𝘦 𝘢𝘳𝘦 𝘤𝘰𝘯𝘥𝘶𝘤𝘵𝘪𝘯𝘨 𝘵𝘩𝘪𝘴 𝘗𝘩𝘢𝘴𝘦 1 𝘣𝘳𝘪𝘥𝘨𝘪𝘯𝘨 𝘴𝘵𝘶𝘥𝘺 𝘵𝘰 𝘵𝘦𝘴𝘵 𝘦𝘹𝘵𝘦𝘯𝘥𝘦𝘥 𝘥𝘰𝘴𝘪𝘯𝘨 𝘰𝘧 𝘔6229 𝘪𝘯 𝘩𝘦𝘢𝘭𝘵𝘩𝘺 𝘢𝘥𝘶𝘭𝘵𝘴. 𝘎𝘪𝘷𝘦𝘯 𝘵𝘩𝘦 𝘳𝘦𝘴𝘶𝘭𝘵𝘴 𝘰𝘧 𝘵𝘩𝘦 𝘧𝘪𝘳𝘴𝘵 𝘪𝘯 𝘩𝘶𝘮𝘢𝘯 𝘴𝘵𝘶𝘥𝘺 𝘪𝘯 𝘤𝘰𝘮𝘣𝘪𝘯𝘢𝘵𝘪𝘰𝘯 𝘸𝘪𝘵𝘩 𝘵𝘩𝘦 𝘴𝘩𝘰𝘳𝘵 𝘩𝘢𝘭𝘧-𝘭𝘪𝘧𝘦 𝘰𝘧 𝘔6229, 𝘸𝘦 𝘣𝘦𝘭𝘪𝘦𝘷𝘦 𝘵𝘩𝘢𝘵 𝘢 𝘱𝘳𝘰𝘭𝘰𝘯𝘨𝘦𝘥 𝘪𝘯𝘧𝘶𝘴𝘪𝘰𝘯 𝘥𝘶𝘳𝘢𝘵𝘪𝘰𝘯 𝘤𝘰𝘶𝘭𝘥 𝘣𝘦 𝘷𝘦𝘳𝘺 𝘦𝘧𝘧𝘦𝘤𝘵𝘪𝘷𝘦 𝘪𝘯 𝘪𝘳𝘳𝘦𝘷𝘦𝘳𝘴𝘪𝘣𝘭𝘺 𝘴𝘵𝘰𝘱𝘱𝘪𝘯𝘨 𝘵𝘩𝘦 𝘩𝘢𝘳𝘮𝘧𝘶𝘭 𝘪𝘯𝘧𝘭𝘢𝘮𝘮𝘢𝘵𝘰𝘳𝘺 𝘳𝘦𝘴𝘱𝘰𝘯𝘴𝘦𝘴 𝘵𝘩𝘢𝘵 𝘰𝘤𝘤𝘶𝘳 𝘪𝘯 𝘴𝘦𝘱𝘴𝘪𝘴 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴. 𝘖𝘯𝘤𝘦 𝘸𝘦 𝘸𝘪𝘭𝘭 𝘩𝘢𝘷𝘦 𝘱𝘰𝘴𝘪𝘵𝘪𝘷𝘦𝘭𝘺 𝘤𝘰𝘯𝘤𝘭𝘶𝘥𝘦𝘥 𝘵𝘩𝘪𝘴 𝘱𝘩𝘢𝘴𝘦 1 𝘴𝘵𝘶𝘥𝘺, 𝘸𝘦 𝘢𝘪𝘮 𝘵𝘰 𝘢𝘱𝘱𝘭𝘺 𝘵𝘩𝘪𝘴 𝘭𝘰𝘯𝘨𝘦𝘳 𝘪𝘯𝘧𝘶𝘴𝘪𝘰𝘯 𝘥𝘶𝘳𝘢𝘵𝘪𝘰𝘯 𝘵𝘰 𝘰𝘶𝘳 𝘱𝘩𝘢𝘴𝘦 2 𝘴𝘵𝘶𝘥𝘺, 𝘸𝘩𝘪𝘤𝘩 𝘪𝘴 𝘤𝘶𝘳𝘳𝘦𝘯𝘵𝘭𝘺 𝘪𝘯 𝘱𝘳𝘦𝘱𝘢𝘳𝘢𝘵𝘪𝘰𝘯” - Kees Groen, CDO

👏 Exciting news from our portfolio company Qorium 👏 Another big step forward in Reinventing Leather 🚀 Congratulations Qorium Team 🚀

🚨 News update from Matisse Pharmaceuticals B.V. - a Brightlands Venture Partners portfolio company developing the first life-saving treatment targeting the root cause of sepsis 👏 Welcome on Board Prof. Carolyn Calfee 𝗠𝗮𝘁𝗶𝘀𝘀𝗲 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 𝗮𝗽𝗽𝗼𝗶𝗻𝘁𝘀 𝗣𝗿𝗼𝗳. 𝗖𝗮𝗿𝗼𝗹𝘆𝗻 𝗖𝗮𝗹𝗳𝗲𝗲 𝘁𝗼 𝘁𝗵𝗲 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗕𝗼𝗮𝗿𝗱 Geleen, October 22, 2024 🎓 Matisse Pharmaceuticals B.V., a clinical stage company developing a medicinal product for the treatment of sepsis, announces the appointment of Prof. Carolyn Calfee to the Scientific Advisory Board. 👩⚕️ Carolyn S. Calfee, MD MAS is Professor of Medicine and Anesthesia at the University of California, San Francisco, where she attends in the intensive care units. She received her medical degree from University of Pennsylvania and completed her residency, chief residency, and fellowship at University of California, San Francisco. Her primary academic focus is the pathogenesis and treatment of the acute respiratory distress syndrome (ARDS), with special interest in molecular phenotypes and precision medicine in critical care, the role of environmental exposures in acute lung injury, and novel treatments for ARDS and sepsis. 🫁 “We are delighted that Carolyn has agreed to strengthen the Scientific Advisory Board. She brings along broad critical care experience with specific knowledge on respiratory infections and sepsis. Her knowledge will be of great importance for taking the right steps to bring the first effective treatment targeting the root cause of sepsis to the millions of patients who need it. With her appointment, we now have a well-balanced board with worldwide renowned sepsis and critical care experts in the US, Canada, UK and the Netherlands”, says Marcel Jacobs, Chief Executive Officer of Matisse pharmaceuticals. 🔬 The Matisse Scientific Advisory Board is chaired by Prof. Chris Reutelingsperger (NL) who is one of the inventors of Matisse’s M6229. The board members include Prof. John Marshall (CAN), Prof. Mervyn Singer (UK), Prof. Tom van der Poll (NL) and Prof. Carolyn Calfee (US). Carolyn, Tom, John and Mervyn are all member of the International Sepsis Forum. The International Sepsis Forum (ISF) is a group of global experts in the epidemiology, pathogenesis, management, outcomes and prevention of Sepsis. 𝗔𝗯𝗼𝘂𝘁 𝗠𝗮𝘁𝗶𝘀𝘀𝗲 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 Matisse Pharmaceuticals B.V. was founded in 2014 in Geleen, the Netherlands. Matisse targets life-threatening inflammation by neutralizing cytotoxic components of the inflammatory system. Its M6229 program is aiming at the development of a medicine to fight sepsis and septic shock. https://lnkd.in/efbrmEEz

🎉 Milestone Achieved! 🎉 We're excited to announce that Hy2Care® BV, a Brightlands Venture Partners portfolio company, has successfully enrolled all patients for the second phase of their pivotal clinical trial! The CartRevive® hydrogel implant, designed to revolutionize cartilage repair, has now been used in 46 patients across leading hospitals in the Netherlands. This is a major step forward in providing innovative solutions for knee cartilage repair and improving patient outcomes. We couldn't be prouder of the Hy2Care team's dedication and innovation! Next stop? U.S. clinical trials and European market entry 🚀 Press release 👇 https://lnkd.in/ePVpksy2 #Innovation #Healthcare #CartilageRepair #BrightlandsVenturePartners #Hy2Care

Dear Network    As we gradually say goodbye to summer and fall is making its entrance, we would like to share with you our whereabouts for the last quarter of the year. There are some exciting events coming up between now and Christmas and we would really like to use these opportunities to connect with you and share our plans for the next year.   Please let us know should you wish to (re-)connect with us, as we are working on exciting new projects.   𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 • 30: Level Up 2024 (Eindhoven 🇳🇱) - Abigail                              𝗢𝗰𝘁𝗼𝗯𝗲𝗿 • 8: LUX Research Client Events (Amsterdam 🇳🇱) – Ilias • 9: Radboudumc Investment Day (Nijmegen 🇳🇱) - Abigail • 10: BLl.INC: Masterclass Investment Landscape (Venlo 🇳🇱) – Marcel • 24: NVP – Annual Conference (Amsterdam 🇳🇱) – Kim • 30: Seminar Growth Across Borders (Maastricht 🇳🇱) - Abigail • 30-31: Impact Festival (Frankfurt 🇩🇪) - Kim   𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 • 4-6: BioEurope Fall (Stockholm 🇸🇪) – Marcel • 7: Impact Festival (The Hague 🇳🇱) – Ilias • 7: Transition to Circularity (Amersfoort 🇳🇱) – Marcel and Kim • 7: Fastlane Graduation Celebration & Networking (Wageningen 🇳🇱) – Kim • 14: Tech Tour Biobased Industries (Wuppertal 🇩🇪) – Olga • 20-21: Slush 2024 (Helsinki 🇫🇮) – Lex   We look forward seeing you!

Last week was the grand opening of the new Experience Center for Circular Plastics at Brightlands Chemelot Campus where ReSolved Technologies is presented. Our advanced dissolution and purification technology addresses complex plastic waste streams for which no adequate recycling solution exists today. Curious about our story, watch our video

Luc Starmans will be representing Brightlands Venture Partners at LSI Europe, the premier European MedTech partnering and investment event 🌍 Are you working on a breakthrough medical technology solution to future-proof our healthcare systems? Shoot Luc a message via the LSI partnering app 📱 #BrightlandsVenturePartners #LSIEurope24 #MedTech #VentureCapital

Happy to announce that Brightlands Venture Partners portfolio company niostem is teaming up with the Max-Planck-Förderstiftung in the quest to provide a true solution for common hair loss 💙

Couldn’t be more proud of the tremendous progress that Vertoro B.V. has made, since the early investment by Brightlands Venture Partners. Vertoro’s leading technology serves an unmet need in the marine biofuel industry by reducing its substantial carbon footprint. https://lnkd.in/e6MRnGFn